Status:
RECRUITING
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In solid cancers, some more aggressive tumor cells actively detach from the primary lesion and then travel through the circulating compartment to reach distant organs and form micro-metastases. These ...
Detailed Description
In solid cancers, after the formation and growth of the primary tumor, some more aggressive tumor cells actively detach from it and then travel through the circulating compartment to reach distant org...
Eligibility Criteria
Inclusion
- The patient is at least 18 years old;
- Patients with pancreatic cancer with remote metastases, naïve of any treatment, that is, eligible for a first line of treatment;
- Patients with oral consent
Exclusion
- Non-affiliation or non-beneficiary of a Social Security regimen;
- Frailty persons according to Article L1121-6 of the CSP;
- Adult protected or unable to give consent as per Article L1121-8 of the CPMP;
- Pregnant or lactating women as per MSC L1121-5.
- Not included for monitoring difficulties (mutation, insufficient motivation, predictable poor compliance, priority associated pathology in care, etc.)
Key Trial Info
Start Date :
June 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT05346536
Start Date
June 16 2022
End Date
December 1 2027
Last Update
July 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Montpellier
Montpellier, France, 34090